Credit Suisse upgraded C4 Therapeutics to Neutral from Underperform with a price target of $10, down from $12.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CCCC:
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- C4 Therapeutics downgraded to Underweight from Neutral at JPMorgan
- C4 Therapeutics reports 2022 EPS ($2.62), consensus ($2.57)
- C4 Therapeutics announces upcoming milestones
- C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights